论文部分内容阅读
美国国立变态反应与传染病研究所的AIDS疫苗临床试验网将对Genentech公司制备的gp120AIDS疫苗进行Ⅰ期人体临床试验。受试对象为28名HIV阴性健康者。研究人员将对10名受试者在第0、4和32周中于肌肉注射100μg剂量的疫苗,并对4名受试者注射安慰剂。如一切正常的话,另外10名受试者将接受300μg剂
The AIDS Vaccine Clinical Trials Network of the National Institute of Allergy and Infectious Diseases will conduct Phase I human clinical trials of the gp120AIDS vaccine manufactured by Genentech. Subjects were 28 HIV-negative healthy subjects. The researchers will administer 10 doses of a 100 μg dose of vaccine to the 10 subjects on weeks 0, 4, and 32 and placebo on 4 subjects. If everything is normal, another 10 subjects will receive 300 μg